Addenbrooke’s Hospital houses one of the top-rated radiotherapy services in the UK. The national agenda is to improve access to Intensity Modulated Radiation Treatment (IMRT). This ability to shape radiation dose precisely to the tumour target means that the amount of radiation received by critical organs and normal tissues surrounding the tumour can be reduced or avoided. This reduces the toxic side-effects of radiotherapy and means that higher radiation doses can be given. The Hospital treats 30% of patients with IMRT, compared to the national average of 13%.
Radiotherapists, physicists and engineers are working together to try and improve treatment for cancer patients. VoxTox is a project that tests computer programs that track how organs move between radiotherapy sessions to minimise any possible damage to healthy tissue. Research shows that organs, such as the prostate, can move by up to 2 cm between radiotherapy sessions, and the resulting damage to surrounding healthy tissues can have lasting effects. The new software (used by the Cavendish Laboratory as part of their work with CERN) will help limit this by providing a clearer picture of exactly how much radiation is hitting the healthy tissues.
Current open trials in Cambridge
The table below lists the current open trials in radiotherapy cancer treatment coordinated by the Cambridge Cancer Trials Centre (last updated 13 July 2016).
|Trial name||Trial description||Contact|
|ENZARAD||Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer||Dr Yvonne Rimmer|
|FAST-Forward Lymph nodes||
Randomised clinical trial testing a 1-week course of curative whole breast radiotherapy against a standard 3-week schedule in terms of local cancer control and late adverse effects in patients with early breast cancer. The lymph node arm of this trial is applicable to patients who have an additional requirement for lymphatic Radiotherapy
|Dr Charlotte Coles|
A multicentre randomised phase II study of
|Dr Yvonne Rimmer|
A phase II study of intensity modulated radiotherapy (IMRT) in primary bone and soft tissue sarcoma.
|Dr Gail Horan|
|Neo-AEGIS||Randomised Clinical Trial of neoadjuvant and adjuvant chemotherapy (Modified MAGIC regimen) vs. neoadjuvant chemoradiation (CROSS protocol) in adenocarcinoma of the oesophagus and oesophago-gastric junction||Dr David Gilligan|
|NIMRAD||A randomised placebo-controlled trial of synchronous NIMorazole versus RADiotherapy alone in patients with locally advanced head and neck squamous cell carcinoma not suitable for synchronous chemotherapy or cetuximab||Dr Richard Benson|
International randomised study of laparoscopic prostatectomy vs stereotactic body radiotherapy (SBRT) and conventional radiotherapy vs SBRT for early stage organ-confined prostate cancer. (currently only open for study B)
|Dr Alex Martin|
|QuaRTUS||A study investigating the feasibility of using ultrasound elastography to more accurately assess the effects of breast radiotherapy||Dr Charlotte Coles|
|RAIDER||A Randomised phase II trial of Adaptive Image guided standard or Dose Escalated tumour boost Radiotherapy in the treatment of transitional cell carcinoma of the bladder||Dr Yvonne Rimmer|
|RAPPER||Radiogenomics: assessment of polymorphisms for predicting the effects of radiotherapy||Prof Neil Burnet|
|SCALOP-2||A multi‐centre randomised study of induction chemotherapy followed by capecitabine (+/‐nelfinavir) with high or standard dose radiotherapy for locally advanced non‐metastatic pancreatic cancer||Dr Thankamma Ajithkumar|
|VoxTox||An observational study to collect comprehensive toxicity data and optimized image data for patients undergoing image guided intensity-modulated radiotherapy for cancers of the head and neck region or the prostate or tumours of central nervous system. These three site specific tumour sites will each be divided into two sub section; discovery (having had radiotherapy treatment up to 4 years ago) and consolidation (due to have radiotherapy treatment and to follow up for a 5 year period there after). The participant will therefore fit into one of the following non randomised arms: Discovery prostate; Consolidation prostate; Discovery head and neck; Consolidation head and neck; Discovery CNS; Consolidation CNS;||Prof Neil Burnet|
If you would like further information about how to take part in any of the clinical trials listed here, please talk to your cancer specialist as patients usually need to be referred by their doctor.
Cambridge Cancer Trials Centre (CCTC) contact for radiotherapy trials: +44(0) 1223 216083 (CCTC general office)